All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

The PROMISE study: What have we learnt about MGUS prevalence and clinical implications?

Jun 21, 2022
Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US. We asked, What have we learnt about monoclonal gammopathy of undetermined significance (MGUS) prevalence and clinical implications?

The PROMISE study: What have we learnt about MGUS prevalence and clinical implications?

Ghobrial begins by outlining the initial results of the PROMISE study, including the benefits of using mass spectrometry for identifying MGUS. Finally, Ghobrial discusses the overall survival and comorbidities that are associated with monoclonal gammopathies.


  1. El-Khoury H, Lee DJ, Alberge JB, et al. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol. 2022;9(5):e340-e349. DOI: 10.1016/S2352-3026(22)00069-2


Subscribe to get the best content related to multiple myeloma delivered to your inbox